Live Breaking News & Updates on Rheumatology

Stay informed with the latest breaking news from Rheumatology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Rheumatology and stay connected to the pulse of your community

Switching From Adalimumab to a Biosimilar

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

Jamiet-brogan , Kostas-botsoglou , Sophia-humphreys , Jordan-axelrad , Peter-lio , Biosimilars , Adalimumab , Switching-therapy , Rheumatology , Dermatology , Gastrointestinal-disease

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.

Ibm , Arthritis-care-research , Arthritis-care , Scan-database , Sex-disparities , Bdmards , Nsaids , Rheumatology ,

SGLT2 Inhibitors Could Play a Role in Treating Gout

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.

Massachusetts , United-states , Chio-yokose , Campbellp-dapagliflozin , Merck-ertugliflozin , Campbellp-empagliflozin-jardiance , Mongan-institute , European-congress-on-rheumatology , Pfizer , Drug-administration , Rheumatology-allergy-clinical-epidemiology-research-center , Allergy-clinical-epidemiology-research-center

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed a dose-response relationship, with higher doses eliciting stronger treatment effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is an immune-mediated inflammatory disease primarily affecting the skin and joints. The immune process is mediated by Interleukin-23, which

Minute-medicine-inc , Rating-level , Psoriasis-area , Severity-index , Dermatology , Il-23 , Il-23-receptor-antagonist , Interleukin-23-receptor-antagonist , Jnj-77242113 , Psoriasis , Rheumatology

Interleukin-23 receptor antagonist improves psoriasis symptoms

1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed a dose-response relationship, with higher doses eliciting stronger treatment effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is an immune-mediated inflammatory disease primarily affecting the skin and joints. The immune process is mediated by

Minute-medicine-inc , Rating-level , Psoriasis-area , Severity-index , Chronic-disease , Dermatology , Interleukin-23-receptor-antagonist , Jnj-77242113 , Psoriasis , Rheumatology ,

In Rheumatic Disease, Cardiovascular Risk is Greatest within First Year of Diagnosis

A Finnish study finds elevated cardiovascular risk in rheumatic diseases peaks within a year of diagnosis, emphasizing the need for early management strategies.

Finland , Drug-administration , Turku-university , Tampere-university-hospital , Semin-arthritis , Rheumatoid , Rheumatology , Cardiology , Cardiovascular-disease , Ra-and-cvd ,

RI medical device company, IlliminOss, develops implants for fragile fractures

https://www.illuminoss.com/us

Anthony-deluise , Deborah-bathgate , Illiminoss-medical , Rhode-island , United-states , Ortho , Prosthetics , Implant , Acute-pain , Bone-fracture , Osteoporosis

KLKB1 gene editing therapy reduces kallikrein levels in hereditary angioedema

1. In this randomized controlled trial, gene-editing therapy targeting the kallikrein B1 gene (KLKB1) led to a significant reduction in plasma kallikrein levels among adults with hereditary angioedema (HA). 2. Trial participants also saw a reduction in angioedema attacks in the following 16 weeks and had no severe adverse events. Evidence Rating Level: 1 (Excellent)

Minute-medicine-inc , Rating-level , Angioedema , Chronic-disease , Crispr-cas9-gene-editing-therapy , Gene-therapy , Hereditary-angioedema , Immunology , Kallikrein , Klkb1 , Klkb1-gene-editing-therapy

Why Are We Letting Insurers Dictate Patient Care?

Prior authorization is wreaking havoc on patient health

United-states , American , Kaiser-family-foundation , American-medical-association , Dyett-desir , Medical-association , Medicare-advantage , Improving-senior-timely-access , Crohn-039s-disease , Rheumatology , Sle

Winter's woes for arthritis sufferers: Life Geisinger offers tips to alleviate pain

When it comes to the cold winter months, people living with arthritis tend to have pain increase with muscle aches and joint pain.This can make day-to-day activ

Pennsylvania , United-states , Teena-kubasti , Cybele-pacheco , Health-medical-pharma , Kubasti , Arthralgia , Arthritis , Rheumatology , Skilled-nursing-facilities ,